Research & Development
Leukemia: Page 2
Taking time out for genetic testing in acute myeloid leukemia may be OK
The retrospective real-world study evaluated outcomes for AML patients included in the Study Alliance Leukemia (SAL) AML registry, which includes 46 treatment centers in Germany. Researchers set out to evaluate how differences in the length of time from diagnosis to start of treatment correlated with overall survival and other key outcomes in patients newly diagnosed with and previously untreated for AML.
June 4, 2020
Invivoscribe garners expanded FDA approval for LeukoStrat CDx
The assay had previously been approved in 2017 as a testing service at Invivoscribe's LabPMM clinical laboratory in San Diego. The new approval paves the way for regional laboratories, cancer treatment centers, and hospitals to perform in-house testing for mutations in the FLT3 gene -- important driver mutations in acute myelogenous leukemia (AML), Invivoscribe said.
May 18, 2020
U.S. cancer death rate drops again
In fact, the decline in cancer mortality from 2016 to 2017 was the largest single-year drop ever recorded, the ACS noted. Overall, the death rate from cancer declined at an annual rate of 1.5% from 2008 to 2017 -- indicating that 2.9 million cancer deaths have been avoided since 1991, according the report, "Cancer Statistics, 2020," published in CA: A Cancer Journal for Clinicians.
January 7, 2020
Sequencing test spots dangerous infections early in kids with cancer
The prospective study of 47 patients evaluated the sensitivity and specificity of the plasma microbial cell-free DNA sequencing (mcfDNA-seq) Karius test for identifying bloodstream infections three days prior to symptoms. The subjects were younger than 25 with relapsed or refractory leukemia treated at St. Jude Children's Research Hospital in Memphis, TN.
December 19, 2019
Fluxion unveils new liquid biopsy panels
Spotlight Myeloid is a 478-amplicon panel covering 23 clinically relevant genes involved in acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms. Meanwhile, the Spotlight EGFR panel offers contiguous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS, using a 17-amplicon design to generate multiplex libraries compatible with sequencing platforms from Illumina, according to the company.
December 15, 2019
AbbVie to deploy Adaptive's clonoSeq test in myeloma trials
Venclexta is currently approved by the U.S. Food and Drug Administration (FDA) for use in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in older patients with newly diagnosed acute myeloid leukemia who can't tolerate intensive chemotherapy. It is being tested for a number of additional indications, including multiple myeloma.
December 8, 2019
Cepheid's leukemia diagnostic receives 510(k) clearance
The test delivers accurate molecular results from whole blood samples in less than three hours, according to the company.
October 1, 2019
Amgen enlists Adaptive's clonoSeq in broad blood cancer deal
MRD-negativity is an increasingly important marker of treatment response in cancer drug development. Per the deal, Adaptive will provide MRD testing and analysis to inform Amgen's drug development and receive annual development fees, sequencing payments, and milestone payments.
September 18, 2019
Written surveys prove best for judging if lab practice guidelines are working
Laboratory practice guidelines provide a framework for the implementation of good laboratory practices. But the effectiveness of guidelines is determined in part by how extensively they are followed and implemented by lab personnel. So, it is important to identify gaps in knowledge and assess adoption to optimize laboratory testing practices in support of patient care.
June 27, 2019
Page 2 of 2